CD8+ T-cell activation pathway

CD8+ T-cell activation pathways involve a multi-step signaling process required for the differentiation of naive CD8+ T cells into cytotoxic T lymphocytes (CTLs) (Source: Janeway's Immunobiology). This process is initiated by Signal 1, the interaction between the T-cell receptor (TCR) and peptide-MHC class I complexes on antigen-presenting cells (Source: NIH/NCBI). Signal 2 involves costimulatory molecules, most notably the binding of CD28 on T cells to CD80/CD86 on dendritic cells, while Signal 3 is provided by cytokines such as IL-2 and IL-12 which drive expansion and survival (Source: Nature Reviews Immunology). In many diseases, particularly cancer, these pathways are inhibited by checkpoints like PD-1 and CTLA-4, which prevent effective anti-tumor immunity (Source: PubMed). Therapeutic strategies, including checkpoint inhibitors and CAR-T cell therapies, aim to manipulate these pathways to restore the immune system's ability to kill target cells (Source: StatPearls). However, over-activation can lead to severe complications such as cytokine release syndrome or autoimmune-like toxicities (Source: FDA/Prescribing Information).

Other names

Cytotoxic T lymphocyte activationCD8+ T cell signalingMHC class I-restricted T cell activationCTL activation

Drugs modulate these pathways by blocking inhibitory checkpoints (e.g., PD-1, CTLA-4), providing agonistic costimulatory signals, or directly engaging the T-cell receptor (TCR) complex to trigger or enhance cytotoxic activity against target cells.